Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
This study seeks to assess the safety and efficacy of treatment with
 ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in non-cirrhotic,
 genotype 1a (GT1a) hepatitis C virus infected participants who are treatment-naïve or
 treatment-experienced with Interferon (IFN) or Pegylated Interferon (pegIFN) with or without
 Ribavirin (RBV).
Inclusion Criteria:

 -  Chronic hepatitis C virus (HCV) infection

 -  Non-cirrhotic subjects

 -  Screening laboratory results showing HCV Genotype 1a (HCV GT1a) infection

 -  HCV treatment-naïve or if treated previously, only with interferon (IFN) or pegylated
 interferon (pegINF) with or without ribavirin (RBV)

 Exclusion Criteria:

 -  Pregnant or breastfeeding women

 -  Positive for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus
 antibody (HIV Ab)

 -  HCV genotype of any subtype other than GT1a or unable to subtype

 -  Prior or current use of any investigational or commercially available anti-HCV agents
 other than IFN, pegIFN or RBV. Subjects with previous participation in trials of
 investigational direct-acting antiviral agents (DAAs) may be enrolled if they can
 produce documentation that they received only placebo.

 -  Current enrollment in another interventional clinical study or receipt of any
 investigational product within 6 weeks prior to study drug administration.